Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 6:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1513–1536 of 8,446 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Metabolism Disorder, Glucose Clear all
Completed Not applicable Interventional

Study of A Cell-Phone System to Improve Health of Youth With Diabetes

NCT02280564
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
health coaching with technology support
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
12 Years to 16 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
3
States / cities
Aurora, Colorado • Raleigh, North Carolina • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 31, 2014 · Synced Oct 23, 2026, 6:17 AM EDT
Completed Not applicable Interventional Results available

PRECISION Study: Multi-center Study of Performance of a Novel Implanted CGM System Using a Next Generation Transmitter and Algorithm

NCT03251079
View directory record Official record
Conditions
Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions
Continuous glucose monitoring system
Device
Lead sponsor
Senseonics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
3
States / cities
Escondido, California • Walnut Creek, California • Renton, Washington
Source: ClinicalTrials.gov public record
Updated Feb 12, 2024 · Synced Oct 23, 2026, 6:17 AM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability and Evidence of Activity Study of UBX1325 in Patients With Diabetic Macular Edema (BEHOLD)

NCT04857996
View directory record Official record
Conditions
Diabetic Macular Edema (DME)
Interventions
UBX1325, Sham
Drug · Other
Lead sponsor
Unity Biotechnology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
19
States / cities
Phoenix, Arizona • Bakersfield, California • Encino, California + 15 more
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 23, 2026, 6:17 AM EDT
Completed Phase 2 Interventional Results available

Study Testing Benefits of Ursolic Acid (UA) as a Countermeasure To Myopenia and Insulin Resistance in Chronic Spinal Cord Injury (SCI)

NCT05776862
View directory record Official record
Conditions
Spinal Cord Injuries, Tetraplegia, Paraplegia, Muscle Loss, Atrophy, Muscular, Insulin Resistance
Interventions
Ursolic Acid, Strength Training
Drug · Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Oct 23, 2026, 6:17 AM EDT
Completed Not applicable Interventional Results available

Improving Diabetes Care Through Effective Personalized Patient Portal Interactions

NCT02953262
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
My HealtheVet Brochure, My HealtheVet Training Guide for Veterans Living with Diabetes, My HealtheVet Group Training, My HealtheVet Individual Training
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 85 Years
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Bedford, Massachusetts • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 28, 2023 · Synced Oct 23, 2026, 6:17 AM EDT
Enrolling by invitation Early Phase 1 Interventional

Truway Diagnostic Tools in Primary Care

NCT07209527
View directory record Official record
Conditions
Chronic Disease, Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight, Hypertension, Cardiovascular Disease Acute, Hyperlipidemia, Chronic Kidney Disease (CKD), Stages 3-4 Exercise Tolerance / Functional Capacity Vascular Health / Arterial Stiffness Fatigue in CKD, Peripheral Artery Disease, Metabolic Syndrome, Prediabetes
Interventions
Truway Portable Ultrasound Device, Truway Blood Glucose Monitor, Standard Oral Hypoglycemic Agent
Device · Drug
Lead sponsor
Truway Health, Inc.
Industry
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 24, 2025 · Synced Oct 23, 2026, 6:17 AM EDT
Completed Not applicable Interventional Results available

A Trial Comparing Continuous Glucose Monitoring With and Without Routine Blood Glucose Monitoring in Adults With Type 1 Diabetes

NCT02258373
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
CGM+BGM, CGM Only
Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
14
States / cities
Beverly Hills, California • San Diego, California • Denver, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Oct 23, 2026, 6:17 AM EDT
Completed Phase 4 Interventional Results available

The Effect of Welchol on Glucose Metabolism in Type 2 Diabetics

NCT00951899
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Colesevelam, Placebo, Diet, Metformin
Drug · Other · Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
35 Years to 70 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 11, 2013 · Synced Oct 23, 2026, 6:17 AM EDT
Withdrawn Phase 2 Interventional

ACZ885 in Type 1 Diabetes Mellitus

NCT01322321
View directory record Official record
Conditions
Diabetes Mellitus, Diabetes Type 1
Interventions
ACZ885, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 35 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 5, 2012 · Synced Oct 23, 2026, 6:17 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Testing the Adipose Expandability Hypothesis In Vivo During Overfeeding

NCT04583514
View directory record Official record
Conditions
Overweight and Obesity, Metabolic Syndrome
Interventions
Control, Overfeeding
Behavioral
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years to 42 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 23, 2026, 6:17 AM EDT
Completed Not applicable Interventional

Improving Diabetes Outcomes for Persons With Severe Mental Illness

NCT02053714
View directory record Official record
Conditions
Diabetes
Interventions
Diabetes self-management and education
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 23, 2026, 6:17 AM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of Technosphere® Insulin Inhalation Powder (TI Inhalation Powder)When an Optimal Dose is Taken With Varied Carbohydrate Intake

NCT00747006
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
Interventions
TI Inhalation Powder and Humalog (Amendment 1), TI Inhalation Powder (original protocol)
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Oct 30, 2014 · Synced Oct 23, 2026, 6:17 AM EDT
Recruiting Not applicable Interventional

Hybrid Closed Loop Effectiveness Trial in Adults With Type 1 Diabetes

NCT06236607
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Diabetes Complications
Interventions
Device specific training, Study clinician/educator visit
Device · Other
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 23, 2026, 6:17 AM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

HomeStyles-Adults of Chinese Heritage

NCT06136793
View directory record Official record
Conditions
Healthy Lifestyle, Home Environment Related Disease, Cardiometabolic Disease, Systemic Inflammatory Response, Health Behavior, Dietary Habits, Physical Inactivity, Self Efficacy, Gut Microbiota, Diabetes Mellitus
Interventions
HomeStyles-China
Behavioral
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
30 Years to 70 Years
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 23, 2026, 6:17 AM EDT
Completed Phase 3 Interventional Results available

A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease

NCT03819153
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Semaglutide, Placebo (semaglutide)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
3,533 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
117
States / cities
Tuscumbia, Alabama • Chula Vista, California • Concord, California + 95 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Oct 23, 2026, 6:17 AM EDT
Completed Phase 3 Interventional

Extension Study for 2993-112

NCT01789957
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
AC2993
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
16 Years to 75 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
219
States / cities
Anniston, Alabama • Birmingham, Alabama • Eclectic, Alabama + 162 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2015 · Synced Oct 23, 2026, 6:17 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Predicting Insulin Resistance in American Indian Youth

NCT00498030
View directory record Official record
Conditions
Insulin Resistance, Stress, Psychological
Interventions
Not listed
Lead sponsor
University of Nebraska
Other
Eligibility
5 Years to 18 Years
Enrollment
202 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2018
U.S. locations
1
States / cities
Rosebud, South Dakota
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 23, 2026, 6:17 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only

NCT02906930
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
semaglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
703 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
56
States / cities
Lancaster, California • Los Angeles, California • Montclair, California + 48 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2022 · Synced Oct 23, 2026, 6:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability Study of Oral LGD-6972 for Type 2 Diabetes Mellitus

NCT02250222
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
LGD-6972, Placebo (Captisol ®)
Drug
Lead sponsor
Ligand Pharmaceuticals
Industry
Eligibility
21 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
3
States / cities
Tempe, Arizona • Miami, Florida • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 11, 2015 · Synced Oct 23, 2026, 6:17 AM EDT
Terminated Phase 4 Interventional Results available

Effect of Saxagliptin Treatment on Myocardial Fat Content, and Monocyte Inflammation

NCT01548651
View directory record Official record
Conditions
Impaired Glucose Tolerance
Interventions
Saxagliptin, Placebo
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
30 Years to 70 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Oct 23, 2026, 6:17 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Effect of Nasal Insulin on Postprandial Glycemic Control in Type 2 Diabetic Patients

NCT00624767
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Insulin (recombinant human insulin), NovoLog
Drug
Lead sponsor
Nastech Pharmaceutical Company, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 20, 2008 · Synced Oct 23, 2026, 6:17 AM EDT
Completed Phase 4 Interventional Results available

A Type 2 Diabetes Study of the Longer-Term Glycemic Effect of AVANDAMET vs. Metformin

NCT00386100
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Avandamet 6 mg/1500 mg (ttd), Avandamet 4 mg/1000 mg (ttd), Avandamet 2 mg/500 mg (ttd), Avandamet 8 mg/ 2000 mg (ttd), Metformin 500 mg (ttd), Metformin 1000 mg (ttd), Metformin 1500 mg (ttd), Metformin 2000 mg (ttd)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
688 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
71
States / cities
Tuscaloosa, Alabama • Gilbert, Arizona • Glendale, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2016 · Synced Oct 23, 2026, 6:17 AM EDT
Not listed Phase 2Phase 3 Interventional

PROVIDENCE:Prevention of Restenosis With Oral Rosiglitazone and the Vision Stent in Diabetics With Coronary Lesions

NCT00116792
View directory record Official record
Conditions
Coronary Artery Disease, Diabetes Mellitus
Interventions
Percutaneous Coronary Intervention (PCI)
Procedure
Lead sponsor
Gold, Herman K., MD
Individual
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 17, 2007 · Synced Oct 23, 2026, 6:17 AM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Implementing Artificial Intelligence to Prevent Vision Loss From Diabetes

NCT07559292
View directory record Official record
Conditions
Vision Disorders, Diabetes
Interventions
AI, Usual Practice
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
22 Years and older
Enrollment
1,700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 23, 2026, 6:17 AM EDT